PATENT CLAIM ANALYSIS

Application Number: 16028235
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "130100"]

Abstract:
The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.

Claim (Index 8):
The method of  claim 1 , wherein treating IPF comprises producing at least a 5% reduction, compared to a baseline measurement, in the extent of pulmonary infiltration of fibroblasts or myofibroblasts, in the rate of collagen deposition, in the degree type II pneumocyte hyperplasia, in the degree of smooth muscle hyperplasia or the formation of fibroblastic foci.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 95.0
- Lexical Diversity: 1.10345
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14398380', '15263767', '12460376', '13374308', '14741747']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7852152089807332
- 35 USC 102 Novelty (BERT): 0.6088478294349497
- Combined Prediction Score: 0.7675784710261548
- Mean Citation Score: 502.49907800000005
- Max Citation Score: 743.4912
- Similarity Product: 441.50249673156736

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test